No Data
No Data
Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13%
Island Pharmaceuticals (ASX:ILA) reallocated $625,000 in grant funding to support a phase two clinical trial investigating the use of the ISLA-101 medication in patients with dengue fever, according t
Island Pharmaceuticals Advances Dengue Fever Treatment With Promising ISLA-101 Study Results
Australian antiviral drug development company Island Pharmaceuticals (ASX: ILA) continues to achieve promising results from testing of a potential treatment for the widely-spread dengue fever.
Island Pharmaceuticals Targets $1.95 Million in New Capital Raise
Island Pharmaceuticals Ltd (ASX:ILA) has opened a fully underwritten, non-renounceable, pro-rata offer for eligible shareholders to raise $1.95 million before costs.
Australia Shares Fall as Central Bank Keeps Rates Steady
Australian shares fell on Tuesday as the country's central bank kept rates steady at its monetary policy meeting. The S&P/ASX 200 Index fell 44.30 points, or 0.6%, to 7,581.60. The Reserve Bank of Aus
Island Pharmaceuticals Achieves Primary Endpoint in Dengue Drug Ascending Dose Study
Island Pharmaceuticals (ASX:ILA) has completed dosing all subjects in its ISLA-101 single ascending dose study, the pharmaceutical firm said on Tuesday. ISLA-101 is being repurposed for the prevention
Island Pharmaceuticals Confirms All Doses in ISLA-101 Study Safe and Well Tolerated by Volunteers
Island Pharmaceuticals Ltd (ASX:ILA) has completed dosing all subjects in its ISLA-101 Single Ascending Dose study, with the Safety Review Committee confirming all three doses was safe and well tolerated, based on a review of available preliminary data.
No Data